A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease (MermaiHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00665223
Recruitment Status : Completed
First Posted : April 23, 2008
Last Update Posted : July 21, 2016
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2011
  Actual Study Completion Date : June 2011
  Certification/Extension First Submitted : February 19, 2013